hers hims semaglutide Full Range of FDA-Approved GLP-1s Available on & Wegovy maker ends partnership with

Betty Jones, compliance senior manager of the accreditation and inspection programs at NABP, says consumers can protect themselves by looking out for red flags

Because of its effectiveness, demand for Wegovy continues to grow

People with a personal or family history of medullary thyroid carcinoma (MTC) or who have multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take Wegovy

Harnessing the cardiovascular benefits of exercise: Are Nrf2 activators useful

Poison center data tracked GLP-1 exposure trends A retrospective analysis of human exposures to GLP-1 RAs reported to the National Poison Data System (NPDS) from January 1, 2012, to December 31, 2023, was conducted